Press Release

Alzheimer’s Disease Diagnostics Market Is Estimated To Record a CAGR of Around 8.90% During The Forecast Period

Life Science

Evolve Business Intelligence has published a research report on the Global Alzheimers Disease Diagnostics Market, 2023–2033. The global Alzheimer’s Disease Diagnostics market is projected to exhibit a CAGR of around 8.90% during the forecast period of 2023 to 2033.

Evolve Business Intelligence has recognized the following companies as the key players in the global Alzheimer’s Disease Diagnostics Market: F. Hoffmann-La Roche, Bristol-Myers Squibb, AstraZeneca PLC, Corium Inc, Eisai Co. Ltd, Biogen Inc, Johnson & Johnson, Eli Lilly and Company, Lupin Limited, AbbVie Inc.


Market Highlights

The Alzheimer’s Disease Diagnostics market is projected to be valued at USD 7.15 Billion by 2033, recording a CAGR of around 8.90% during the forecast period. Alzheimer’s disease diagnostics refers to the process of identifying and assessing the presence and severity of Alzheimer’s disease in individuals. This diagnostic procedure typically involves a combination of medical history evaluation, cognitive testing, neurological examinations, brain imaging techniques such as MRI and PET scans, and sometimes cerebrospinal fluid analysis. These assessments aim to detect cognitive impairments, memory deficits, and other neurological abnormalities characteristic of Alzheimer’s disease. Early and accurate diagnosis of Alzheimer’s is crucial for appropriate treatment and care planning, as well as for advancing research into potential therapies and interventions to improve the quality of life for affected individuals.

For More Information :


The COVID-19 pandemic had a profound and enduring impact on the Alzheimer’s Disease Diagnostics market. While the immediate focus of healthcare resources shifted to managing the pandemic, routine medical checkups and non-urgent appointments, including Alzheimer’s screenings, were postponed or canceled, leading to a decrease in early detection and diagnosis. Additionally, the redirection of research efforts and funding toward COVID-19-related studies temporarily slowed down advancements in Alzheimer’s diagnostics and therapeutic development. However, the pandemic also accelerated the adoption of telemedicine and remote monitoring technologies, which could potentially improve access to Alzheimer’s diagnostics in the long term. As the world recovers from the pandemic’s aftermath, efforts to bolster Alzheimer’s diagnostics, raise awareness, and invest in research are expected to resume, driven by the ongoing need to address the growing public health challenge of Alzheimer’s disease.

Segmental Analysis

The global Alzheimer’s Disease Diagnostics market has been segmented based on Type, Diagnostic Test, End User, and region.

Based on the Type, the Alzheimer’s Disease Diagnostics market is segmented based on Nervous System, Examination, Genetic Testing, Minor Mental State Examination, and Brain Imaging. Nervous Systems are expected to have the largest market share throughout the forecast period, while Examination is expected to grow at the fastest rate.

Based on the Diagnostic Test, the global Alzheimer’s Disease Diagnostics market has been divided into Genetic Testing, Positron Emission Tomography, Electroencephalography, Magnetic Resonance Imaging, Computed Tomography, Neurological Exam, Mini-mental State Exam (MMSE), Brain Imaging, and Others. The Genetic Testing segments are anticipated to dominate the market.

Based on the End User, the global Alzheimer’s Disease Diagnostics market has been divided into Clinics, Hospitals, Diagnostic Centers, Pharmaceutical Companies, and Academic Research Centers. The Clinics segments are anticipated to dominate the market.

For More Information :


Regional Analysis

The Alzheimer’s Disease Diagnostics market is divided into six regions: North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. North America region includes countries in North America, such as the U.S. and Canada, which are significant players in healthcare and have a relatively high prevalence of Alzheimer’s disease. Encompassing countries in Europe, this region also plays a crucial role in Alzheimer’s diagnostics, with several leading research institutions and healthcare providers. This region consists of countries in the Asia Pacific, including China, Japan, India, Australia, and others. The Asia-Pacific region has seen an increase in the prevalence of Alzheimer’s disease due to aging populations. Comprising countries in Central and South America, this region has also seen a rise in Alzheimer’s cases, making it an important market for diagnostics and healthcare. The Middle East region includes countries in the Middle East, where healthcare infrastructure and diagnostics for Alzheimer’s disease have been developing steadily. Africa region also plays a role in Alzheimer’s diagnostics, with efforts to improve healthcare access and awareness about the disease’s impact on aging populations.


Leave a Reply

Your email address will not be published. Required fields are marked *